Jason Coloma, Maze Therapeutics CEO

Maze Ther­a­peu­tics spins out two new com­pa­nies with Al­loy and Bridge­Bio

The start­up has be­come the starter.

Just un­der two years af­ter burst­ing on­to the scene with close to $200 mil­lion, Maze Ther­a­peu­tics is spin­ning out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.